Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Fleming AD, Palka P, McDicken WN, Fenn LN, Sutherland GR. Verification of cardiac Doppler tissue images using grey-scale M-mode images. Ultrasound Med Biol. 1996 Jan 1;22(5):573-81. doi: 10.1016/0301-5629(95)02065-9
Fleming AD, McDicken WN, Sutherland GR, Hoskins PR. Assessment of colour Doppler tissue imaging using test-phantoms. Ultrasound Med Biol. 1994 Jan 1;20(9):937-51. doi: 10.1016/0301-5629(94)90053-1